Natural Investments LLC Sells 1,539 Shares of Danaher Corporation $DHR

Key Points

• Natural Investments LLC reduced its stake in Danaher Corporation by 36.5%, selling 1,539 shares during the second quarter, resulting in total holdings valued at $529,000.
• Several other hedge funds increased their positions in Danaher, with Conning Inc. raising its stake by 10.2% to own 23,581 shares valued at $4,658,000.
• Danaher Corporation's stock has been rated with a consensus rating of "Moderate Buy" and a price target of $244.60 based on reports from equities research analysts.

Natural Investments LLC decreased its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 36.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,682 shares of the conglomerate's stock after selling 1,539 shares during the quarter. Natural Investments LLC's holdings in Danaher were worth $529,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Conning Inc. raised its stake in Danaher by 10.2% during the second quarter. Conning Inc. now owns 23,581 shares of the conglomerate's stock valued at $4,658,000 after purchasing an additional 2,181 shares in the last quarter. Eastern Bank raised its stake in Danaher by 1.6% during the second quarter. Eastern Bank now owns 186,533 shares of the conglomerate's stock valued at $36,848,000 after purchasing an additional 2,958 shares in the last quarter. Aberdeen Group plc raised its stake in Danaher by 4.7% during the second quarter. Aberdeen Group plc now owns 1,158,897 shares of the conglomerate's stock valued at $229,334,000 after purchasing an additional 52,124 shares in the last quarter. Lmcg Investments LLC raised its stake in Danaher by 11.4% during the second quarter. Lmcg Investments LLC now owns 115,839 shares of the conglomerate's stock valued at $22,883,000 after purchasing an additional 11,851 shares in the last quarter. Finally, Blue Zone Wealth Advisors LLC raised its stake in Danaher by 12.8% during the second quarter. Blue Zone Wealth Advisors LLC now owns 21,683 shares of the conglomerate's stock valued at $4,283,000 after purchasing an additional 2,462 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on DHR shares. Barclays reaffirmed an "overweight" rating and set a $225.00 price target (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Redburn Partners set a $220.00 price target on shares of Danaher in a research note on Wednesday. Wells Fargo & Company reduced their target price on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Bank of America reduced their target price on shares of Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a research note on Monday, September 22nd. Finally, Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a research note on Tuesday, September 2nd. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and a consensus price target of $244.60.

Danaher Trading Down 1.0%

NYSE DHR opened at $202.53 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The company has a market capitalization of $145.02 billion, a price-to-earnings ratio of 43.09, a price-to-earnings-growth ratio of 2.88 and a beta of 0.77. The company's 50-day simple moving average is $200.66 and its two-hundred day simple moving average is $197.16. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same period last year, the business earned $1.72 EPS. The company's revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher's payout ratio is presently 27.23%.

Insider Buying and Selling

In other news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.